Daybreak Capital Partners
Daybreak Capital Partners

  • Healthcare

    The Healthcare practice is predominantly focused on life science companies in the medical device, pharmaceutical, biotechnology, diagnostics and other healthcare markets.  Strategic areas of focus within the practice include traditional and biotech based pharmaceuticals; blood products; diagnostics; cardiovascular, orthopedic and dental devices; wound care and data-driven health IT applications.

    The team has held a broad range of executive and operational roles within industry, executing various healthcare merger and acquisition transactions while in operating roles with venture-backed, private and public companies, as well as serving as advisor to small and large multinational companies to assist them in implementing strategies to improve profitability and expand markets for their products.

    The team’s worldwide contacts and deep sector knowledge, including strong therapeutic and clinical understanding, better enables us to constructively assess opportunities and maximize transaction outcomes.

    Team members have represented companies across a broad spectrum of the medical device and health IT marketplace.  Sector experience includes wound care products, orthopedic and dental implants, imaging, cardiovascular devices, point of care diagnostics, biotech-based manufacturing services, imaging technologies, drug discovery services, surgical equipment, health services CRM, disease management services, among others.

    Relevant Transactions

    Professionals

    Jon Tebol, Ken West, Jan Turek, Jim Woodward, Ajay Khanna 


    Note: The Polarean transactions were led by Mr. Tebol while at Daybreak Capital. The Encelle, Accordant and Cardio Metrics transactions were executed by Mr. Woodward in his operating capacities with those companies. The Embrex transaction was executed by Mr. West in his operating capacity with that company and the VetIniste transaction was executed by him while at TCG. The Biolex and Bayer transactions were executed by Mr. Turek in his operating capacities with those companies.  The Johnson & Johnson transaction was executed by Mr. Burns in his operating capacities with those companies.  The Spectera Dental and SRA Technologies transactions were led by Mr. Tebol while a Managing Director at Tucker Anthony Sutro and Specialty Coating Systems while at Stifel Nicolaus & Company.